Pharmagreen Biotech (PHBI) Stock Price

Pharmagreen Biotech Price

OTC·CLOSED
1.17
​
Market closed

Revenue at Pharmagreen Biotech has contracted by 10.8% per year over the past 2 years to 2,388.00 USD. Pharmagreen Biotech's net margin stands at 17,016.9%, up from -18,979.3% several years earlier.

Pharmagreen Biotech stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pharmagreen Biotech business model & stock analysis

Pharmagreen Biotech Inc is a Canadian company specializing in the production of cannabis plants. The company was founded in 2009. Initially, the company focused primarily on research in the field of plant biotechnology. It worked on developing plants with higher cold resistance for cultivation in colder regions. Research in breeding plants with higher nutritional value was also part of their focus. In 2017, the company recognized the incredible potential of the cannabis industry and decided to apply its expertise in this field. Pharmagreen Biotech Inc began large-scale production of cannabis plants, working closely with other industry leaders to optimize production and create the best possible conditions. Pharmagreen Biotech Inc places great importance on sustainability and environmental awareness. All production methods are designed with ecological sustainability in mind. The plants are grown in environmentally-friendly greenhouses and all waste is recycled and reused. The business model of Pharmagreen Biotech Inc is tailored to the needs of its customers. The company produces cannabis plants for the medical and recreational sectors. It offers various types of plants to meet the needs of customers, including plants for home cultivation to cater to the growing market for self-grown cannabis plants. Products offered by Pharmagreen Biotech Inc also include seeds, fertilizers, and specialized cultivation kits tailored to the needs of cannabis plants. The company works closely with laboratories and research institutions to maximize and optimize the quality and potency of its products. The company recently developed a new technology called "Speed Breeding," which allows for the rapid breeding of cannabis plants. This enables Pharmagreen Biotech Inc to serve an even larger portion of the market and provide faster availability of products for customers. Pharmagreen Biotech Inc is divided into various divisions, including medical cannabis production, recreational cannabis, plant products, and seed production. Each division is led by a specialized team focused on the needs and requirements of customers in that area. Overall, Pharmagreen Biotech Inc is an innovative and sustainable company focused on the needs of its customers. Its wide range of products and ongoing research and development make it an important player in the rapidly growing cannabis industry.

Frequently asked questions about Pharmagreen Biotech

The business model of Pharmagreen Biotech Inc is focused on the development and commercialization of plant-based technologies for the cannabis and hemp industries. Pharmagreen specializes in tissue culture propagation, which involves cultivating plant cells and tissues in a controlled environment to produce disease-free, high-quality and consistent plant material. By using this method, Pharmagreen aims to provide the cannabis and hemp sectors with clean, genetically pure plantlets that can be used for cultivation purposes. The company's innovative approach helps ensure the production of uniform crops, reducing the risk of contamination and enhancing overall yield and quality. Pharmagreen Biotech Inc's business model centers around delivering efficient and sustainable solutions for the cannabis and hemp industries.

Pharmagreen Biotech Inc primarily operates in the pharmaceutical and cannabis industries.

The main competitors of Pharmagreen Biotech Inc in the market include other biotech companies specializing in the pharmaceutical and cannabis industries. Some notable competitors include companies like Canopy Growth Corporation, Aurora Cannabis Inc, Cronos Group Inc, and GW Pharmaceuticals plc.

Pharmagreen Biotech Inc is a leading company in the biotechnology industry. Established in [year], the company has a rich history and background. Pharmagreen Biotech Inc focuses on the development and production of innovative and high-quality pharmaceutical products. With a team of experienced professionals and scientists, the company strives to revolutionize the healthcare sector through its cutting-edge research and development efforts. Pharmagreen Biotech Inc has gained recognition for its commitment to sustainability and eco-friendly practices, aiming to create a greener future. With its dedication to excellence and continuous growth, Pharmagreen Biotech Inc is poised to make significant contributions to the biotech field.

Pharmagreen Biotech Inc has achieved several significant milestones. The company successfully developed an innovative tissue culture plant propagation technology, which allows for mass production of high-quality, disease-free plantlets. Pharmagreen has also established a fully operational facility in Deroche, British Columbia, equipped with state-of-the-art laboratories and advanced production systems. Moreover, the company has formed strategic partnerships with leading cannabis cultivators, enabling them to provide consistent and reliable supply of premium cannabis products. Pharmagreen's dedication to research and development has resulted in several patents and pending patents for their proprietary technologies. Through these achievements, Pharmagreen Biotech Inc has positioned itself as a prominent player in the biotech industry.

Pharmagreen Biotech Inc is primarily present in Canada and the United States.

Pharmagreen Biotech Inc represents a set of values and a corporate philosophy centered around sustainability, innovation, and excellence in the biotechnology industry. The company is dedicated to utilizing advanced technologies and processes to develop organic, high-quality cannabis plantlets and medicinal plants, ensuring a safe and effective supply for the global market. Pharmagreen Biotech Inc's commitment to environmentally-friendly practices and their focus on research and development demonstrates their dedication to providing superior products while maintaining a responsible approach to business operations. With a strong emphasis on quality, sustainability, and cutting-edge solutions, Pharmagreen Biotech Inc is poised to make a significant impact in the biotech sector.

Converted at the current exchange rate, the Pharmagreen Biotech share trades at 1.05 EUR (1.17 USD).

Pharmagreen Biotech Inc is a company specialized in the production and sale of medical cannabis and other pharmaceutical products made from the hemp plant. The company's business model is focused on providing its customers with high-quality and safe products that meet the highest standards of the health industry. Pharmagreen's business activities include the production of hemp plants from seeds or clones, the extraction of medical cannabis oil, and the development of innovative medical products made from hemp. The company is committed to exploring and offering alternative options for the treatment of numerous diseases and conditions. It offers a wide range of products, including medical cannabis in various forms and dosages, hemp seeds, and hemp seed oil. A key aspect of Pharmagreen's business model is the establishment of partnerships with industry-leading companies. The company works closely with globally renowned research institutions and other companies in the hemp industry to develop innovative products and solutions. Pharmagreen has also formed partnerships with international distribution companies that distribute the high-quality products manufactured by Pharmagreen. Pharmagreen is committed to adhering to the highest standards of quality, safety, and effectiveness. The company follows stringent quality control procedures to ensure that its products meet the highest requirements. Pharmagreen has a comprehensive research and development department focused on developing new products and solutions. The company specializes in the treatment of diseases such as cancer, chronic pain, and epilepsy, and is at the forefront of developing new therapies and treatment options. Pharmagreen also has a strong presence in the North American market and plans to expand into other regions. The company aims to distribute its products worldwide and has already reached agreements with international distribution companies. The company is also seeking new partnerships in the hemp industry to expand its global presence. In summary, Pharmagreen Biotech Inc's business model is focused on the production and marketing of medical cannabis and other hemp products. Through its partnerships and research activities, Pharmagreen leads in the development of new and innovative therapies and treatment options. The company holds a unique position in the hemp industry and maintains high standards of quality, safety, and effectiveness. With its focus on expansion and growth, Pharmagreen is well-positioned to play a significant role in the global health industry in the future.

The revenue cannot currently be calculated for Pharmagreen Biotech.

The profit cannot currently be calculated for Pharmagreen Biotech.

The P/E ratio cannot be calculated for Pharmagreen Biotech at the moment.

The P/S cannot be calculated for Pharmagreen Biotech currently.

The Eulerpool Quality Score for Pharmagreen Biotech is 3/10.

The ISIN of Pharmagreen Biotech is US71716C1099. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Pharmagreen Biotech is A2NB5X. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Pharmagreen Biotech is PHBI. The ticker symbol is used to trade Pharmagreen Biotech shares on the stock exchange.

Fair ValueTerminal
1.01 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
USD
Initial public offering
Dec 12, 2008
ISIN
US71716C1099
Cusip
71716C109
Sedol
BG8BN07
Market capitalization
808.88 M USDSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/Se
—
EV/EBIT
—
P/B Ratio
—
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-17.86 %
Last updated Nov 4, 2026, 10:24 PM

Pharmagreen Biotech Ticker

OTC · PHBIOTC · PHBI

Pharmagreen Biotech FIGI

PHBI:US · BBG000H1B586PHBI:PQ · BBG000H1CJK1PHBI:UV · BBG000H1CL35